[USPRwire, Thu Aug 22 2019] This report on the
rheumatoid arthritis drugs market analyzes the current and future scenario of the global market.
[ClickPress, Thu Aug 22 2019] This report on the
rheumatoid arthritis drugs market analyzes the current and future scenario of the global market.
Rheumatoid Arthritis (RA) is a prevailing and debilitating autoimmune disease; characterized by chronic inflammation and joint destruction.1 It is a systemic disease that causes both cartilage and joint destruction leading to loss of function.
Methotrexate (MTX) is positioned as the anchor drug for
rheumatoid arthritis treatment.(5) For
rheumatoid arthritis, it is believed that MTX regulates cell growth by inhibiting folate metabolism in lymphocytes and other cells, and also has an anti-inflammatory mechanism through the promotion of adenosine synthesis in vascular endothelial cells and other cells in synovial membranes.
Patients with
rheumatoid arthritis have an approximately 50 per cent higher risk of experiencing cardiovascular events such as heart attack and stroke compared with the general population.
Corticosteroids prescribed before embryo transfer might have improved the likelihood of live birth in these women with
rheumatoid arthritis, according to the investigators, led by Professor Bente Mertz Norgard of the center for clinical epidemiology at the Odense (Denmark) University Hospital.
Patients and Methods: Total 140 diagnosed patients of
rheumatoid arthritis by criteria ACR 2010 were included in this study.
- North Chicago, Illinois-based global biopharmaceutical company AbbVie (NYSE: ABBV) has presented new patient-reported outcome data during the Annual European Congress of Rheumatology from three SELECT Phase 3 trials evaluating upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor, in adult patients with moderate to severe
rheumatoid arthritis, the company said.
Pleural disease is the most frequent intrathoracic manifestation of
rheumatoid arthritis (RA) and causes pleural effusion in up to 20% of patients, although clinically apparent in only 5% [1].